Osteoporosis International

, Volume 16, Issue 11, pp 1345–1352 | Cite as

Bone mass and mineral metabolism in HIV+ postmenopausal women

  • Michael Yin
  • Jay Dobkin
  • Karen Brudney
  • Carolyn Becker
  • Janis L. Zadel
  • Monica Manandhar
  • Vicki Addesso
  • Elizabeth Shane
Original Article

Abstract

The objective of this cross-sectional study was to estimate the prevalence of and risk factors for osteoporosis in HIV+ postmenopausal women. Bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) and biochemical indices of mineral metabolism were measured in 31 Hispanic and African American HIV+ postmenopausal women. BMD was compared with 186 historical controls, matched for age, ethnicity and postmenopausal status. Mean BMD was significantly lower at the lumbar spine and total hip in the HIV+ group, as compared with controls. Prevalence of osteoporosis was higher in the HIV+ group than controls at the lumbar spine (42% vs 23%, p =0.03) and total hip (10% vs 1%, p =0.003). Among HIV+ women, time since menopause and weight were significant predictors of BMD, while duration or class of antiretroviral therapy (ART), AIDS diagnosis, nadir CD4, steroid use, and vitamin D deficiency were not. Prevalence of osteoporosis is substantially higher in HIV+ Hispanic and African-American postmenopausal women than in controls. Established osteoporosis risk factors were more important in predicting BMD than factors associated with HIV infection and ART. Long-term management of the growing female HIV population should include the evaluation for and management of osteoporosis.

Keywords

Bone metabolism HIV Osteoporosis Postmenopausal women 

References

  1. 1.
    Lahdevirta J et al (1988) Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 85(3):289–291Google Scholar
  2. 2.
    Manolagas SC (1995) Role of cytokines in bone resorption. Bone 17 [Suppl 2]:63S–67SGoogle Scholar
  3. 3.
    Roodman GD (1993) Role of cytokines in the regulation of bone resorption. Calcif Tissue Int 53 [Suppl 1]:S94–98Google Scholar
  4. 4.
    Breen EC et al (1990) Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 144(2):480–484Google Scholar
  5. 5.
    Aukrust P et al (1994) Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection—correlations to clinical, immunologic, and virologic parameters. J Infect Dis 169(2):420–424. Erratum: J Infect Dis 169(5):1186–1187Google Scholar
  6. 6.
    Aukrust P et al (1999) Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 84(1):145–50Google Scholar
  7. 7.
    Dobs AS et al (1988) Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 84 3(Part 2):611–616Google Scholar
  8. 8.
    Haug CJ et al (1998) Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab 83(11):3832–3838Google Scholar
  9. 9.
    Huang JS et al (2001) Reduced bone density in androgen-deficient women with acquired immune deficiency syndrome wasting. J Clin Endocrinol Metab 86(8):3533–3539Google Scholar
  10. 10.
    Jain RG, JM Lenhard (2002) Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem 277(22):19247–19250Google Scholar
  11. 11.
    Wang MWH, Teitelbaum SL, Tebas P, Powderly WG, Ross FP (2001) Indinavir inhibits bone formation while ritonavir inhibits osteoclast differentiation and function. In: Eighth Conference on Retroviruses and Opportunistic Infections, Abstract 541Google Scholar
  12. 12.
    Wang MWH, Wei S, Teitelbaum SL, Ross FP (2002) HIV protease inhibitor indinavir impairs osteoblastic bone formation, in vivo and in vitro. In: ASBMR 24th Meeting, Abstract SA333Google Scholar
  13. 13.
    Paton NI et al (1997) Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int 61(1):30–32Google Scholar
  14. 14.
    Tebas P et al (2000) Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. [see comments] AIDS 14(4):F63–67Google Scholar
  15. 15.
    Knobel H et al (2001) Osteopenia in HIV-infected patients: Is it the disease or is it the treatment? AIDS 15(6):807–808Google Scholar
  16. 16.
    Lawal A et al (2001) Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy. AIDS 15(2):278–280Google Scholar
  17. 17.
    Teichmann J et al (2003) Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect 46(4):221–227Google Scholar
  18. 18.
    Dolan SE, Huang JE, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S (2003) Reduced bone density in HIV-infected women. In: Fifth International Workshop on Adverse Drug Reactions and Lipodystrophy, Paris, Abstract 23Google Scholar
  19. 19.
    Arnsten JH, Freeman R, Santoro N, Schoenbaum EE (2003) HIV infection and protease-inhibitor use are not associated with reduced bone mineral density in older HIV-infected women. In: Tenth Conference on Retroviruses and Opportunistic Infections, Abstract 103Google Scholar
  20. 20.
    Rea JA et al (2001) Visual assessment of vertebral deformity by X-ray absorptiometry: a highly predictive method to exclude vertebral deformity. Osteoporos Int 2000 11(8):660–668. Erratum: Osteoporos Int 12(4):336Google Scholar
  21. 21.
    Rea JA et al (2000) Morphometric X-ray absorptiometry and morphometric radiography of the spine: a comparison of prevalent vertebral deformity identification. J Bone Miner Res 15(3):564–574Google Scholar
  22. 22.
    Mazess RB et al (1990) Dual-energy X-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr 51(6):1106–1112Google Scholar
  23. 23.
    Gao P et al (2001) Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1–84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16(4):605–614PubMedGoogle Scholar
  24. 24.
    Gundberg CM et al (1985) Determination of osteocalcin in human serum: results with two kits compared with those by a well-characterized assay. Clin Chem 31(10):1720–1723Google Scholar
  25. 25.
    Clemens JD et al (1997) Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 43(11):2058–2063Google Scholar
  26. 26.
    Murillo-Uribe A, D-HM, Aguirre E et al (1999) Osteoporosis en la mujer postmenopausica mexicana: Magnitud del problema. Estudio Multicentrico. Ginecol Obstet Mex 67:227–233Google Scholar
  27. 27.
    Bauer RL, RA Deyo (1987) Low risk of vertebral fracture in Mexican-American women. Arch Intern Med 147(8):1437–1439Google Scholar
  28. 28.
    Harris SS et al (2000) Vitamin D insufficiency and hyperparathyroidism in a low-income, multiracial, elderly population. J Clin Endocrinol Metab 85(11):4125–4130CrossRefPubMedGoogle Scholar
  29. 29.
    Hannon R, Eastell R (2000) Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 11 [Suppl 6]:S30–44Google Scholar
  30. 30.
    Finkelstein JS et al (2002) Ethnic variation in bone turnover in pre- and early perimenopausal women: effects of anthropometric and lifestyle factors. J Clin Endocrinol Metab 87(7):3051–3056Google Scholar
  31. 31.
    Jacobson D, Knox T, Shevitz S, Gorbach S (2003) Low bone mineral density in HIV-infected women. In: Tenth Conference on Retroviruses and Opportunistic Infections, Abstract 102Google Scholar
  32. 32.
    Pacifici R (1996) Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 11(8):1043–1051Google Scholar
  33. 33.
    Aukrust P et al (1999) Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: Persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis 179(1):74–82Google Scholar
  34. 34.
    Ledru E et al (2000) Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 95(10):3191–3198. Erratum: Blood 2000 96(5):1673Google Scholar
  35. 35.
    Hofbauer LC et al (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15(1):2–12PubMedGoogle Scholar
  36. 36.
    Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142(12):5050–5055CrossRefPubMedGoogle Scholar
  37. 37.
    Fakruddin JM, Laurence J (2002) HIV-1 modulates TRANCE expression in vitro and in vivo: potential mechanism for the osteopenia of HIV disease. Ninth Conference on Retroviruses and Opportunistic Infections, Abstract 714-TGoogle Scholar
  38. 38.
    Fakruddin JM, Laurence J (2003) HIV envelope gp 120-mediated regulation of osteoclastogenesis via RANKL secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 278(48):48251–48258Google Scholar
  39. 39.
    Eghbali-Fatourechi G et al (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111(8):1221–1230CrossRefPubMedGoogle Scholar
  40. 40.
    Hofbauer LC et al (1999) Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140(9):4367–4370CrossRefPubMedGoogle Scholar
  41. 41.
    Nolan D et al (2001) Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 15(10):1275–1280Google Scholar
  42. 42.
    Mondy K et al (2003) Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36(4):482–490Google Scholar
  43. 43.
    Struble KMJ, Schneider B, Soon G (2001) Bone fracture rates in HIV+ patients receiving PI vs non-PI regimens. In: Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract I-1329Google Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2005

Authors and Affiliations

  • Michael Yin
    • 1
    • 4
  • Jay Dobkin
    • 1
  • Karen Brudney
    • 1
  • Carolyn Becker
    • 2
  • Janis L. Zadel
    • 1
  • Monica Manandhar
    • 3
  • Vicki Addesso
    • 2
  • Elizabeth Shane
    • 2
  1. 1.PH8–876, Division of Infectious DiseasesDepartment of Medicine, Columbia College of Physicians and SurgeonsNew YorkUSA
  2. 2.Division of Endocrinology, Department of MedicineColumbia College of Physicians and SurgeonsNew YorkUSA
  3. 3.Division of Infectious Diseases, Department of MedicineBeth Israel Deaconess Medical CenterBostonUSA
  4. 4.PH8–876New YorkUSA

Personalised recommendations